The efficacy of ranibizumab treatment in clinical practice in
patients with the wet form of age-related macular degeneration.
The results of the Czech National Registry

J 2015

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

CHRAPEK, Oldřich, Jiří JARKOVSKÝ, Jan STUDNICKA, Martin SIN, Petr KOLÁŘ et. al.

Základní údaje

Originální název

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Autoři

CHRAPEK, Oldřich (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Jan STUDNICKA (203 Česká republika), Martin SIN (203 Česká republika), Petr KOLÁŘ (203 Česká republika, garant, domácí), Barbora JIRKOVA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Sarka PITROVA (203 Česká republika) a Jiri REHAK (203 Česká republika)

Vydání

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Palacký University, 2015, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.924

Kód RIV

RIV/00216224:14110/15:00084535

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2015.017

UT WoS

000364948100012

Klíčová slova anglicky

age-related macular degeneration; ranibizumab

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 11. 2019 12:37, Mgr. Tereza Miškechová

Anotace

V originále

Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. Results. After 12 months of treatment, a loss of < 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of >/= 15 letters was found in 9.7% of eyes on ranibizumab. The results for our patients treated in clinical practice with ranibizumab were poorer than those in the SUSTAIN (Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) study. A rationale for this was sought in a sub-analysis. Conclusions. Sub-analysis demonstrated that treatment naive CNV (choroidal neovascularization), occult CNV and lower height of the macular oedema at the outset of the disease may be positive prognostic factors for final visual acuity in anti-VEGF (vascular endothelial growth factor) treated patients.

Citovat

CHRAPEK, Oldřich, Jiří JARKOVSKÝ, Jan STUDNICKA, Martin SIN, Petr KOLÁŘ, Barbora JIRKOVA, Ladislav DUŠEK, Sarka PITROVA a Jiri REHAK. The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry. Biomedical Papers of the Faculty of Medicine of Palacký University. Olomouc: Palacký University, 2015, roč. 159, č. 3, s. 407-412. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2015.017.

@article{1316048,
   author = {Chrapek, Oldřich and Jarkovský, Jiří and Studnicka, Jan and Sin, Martin and Kolář, Petr and Jirkova, Barbora and Dušek, Ladislav and Pitrova, Sarka and Rehak, Jiri},
   article_location = {Olomouc},
   article_number = {3},
   doi = {http://dx.doi.org/10.5507/bp.2015.017},
   keywords = {age-related macular degeneration; ranibizumab},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers of the Faculty of Medicine of Palacký University},
   title = {The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry},
   volume = {159},
   year = {2015}
}

TY  - JOUR
ID  - 1316048
AU  - Chrapek, Oldřich - Jarkovský, Jiří - Studnicka, Jan - Sin, Martin - Kolář, Petr - Jirkova, Barbora - Dušek, Ladislav - Pitrova, Sarka - Rehak, Jiri
PY  - 2015
TI  - The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry
JF  - Biomedical Papers of the Faculty of Medicine of Palacký University
VL  - 159
IS  - 3
SP  - 407-412
EP  - 407-412
PB  - Palacký University
SN  - 12138118
KW  - age-related macular degeneration
KW  - ranibizumab
N2  - Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. Results. After 12 months of treatment, a loss of < 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of >/= 15 letters was found in 9.7% of eyes on ranibizumab. The results for our patients treated in clinical practice with ranibizumab were poorer than those in the SUSTAIN (Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) study. A rationale for this was sought in a sub-analysis. Conclusions. Sub-analysis demonstrated that treatment naive CNV (choroidal neovascularization), occult CNV and lower height of the macular oedema at the outset of the disease may be positive prognostic factors for final visual acuity in anti-VEGF (vascular endothelial growth factor) treated patients.
ER  -

CHRAPEK, Oldřich, Jiří JARKOVSKÝ, Jan STUDNICKA, Martin SIN, Petr KOLÁŘ, Barbora JIRKOVA, Ladislav DUŠEK, Sarka PITROVA a Jiri REHAK. The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry. \textit{Biomedical Papers of the Faculty of Medicine of Palacký University}. Olomouc: Palacký University, 2015, roč.~159, č.~3, s.~407-412. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2015.017.

Podrobný výpis o publikaci